98%
921
2 minutes
20
Cell-cell fusion is a tightly controlled process in the human body known to be involved in fertilization, placental development, muscle growth, bone remodeling, and viral response. Fusion between cancer cells results first in a whole-genome doubled state, which may be followed by the generation of aneuploidies; these genomic alterations are known drivers of tumor evolution. The role of cell-cell fusion in cancer progression and treatment response has been understudied due to limited experimental systems for tracking and analyzing individual fusion events. To meet this need, we developed a molecular toolkit to map the origins and outcomes of individual cell fusion events within a tumor cell population. This platform, ClonMapper Duo ('CMDuo'), identifies cells that have undergone cell-cell fusion through a combination of reporter expression and engineered fluorescence-associated index sequences paired to randomly generated nucleotide barcodes. scRNA-seq of the indexed barcodes enables the mapping of each set of parental cells and fusion progeny throughout the cell population. In triple-negative breast cancer cells CMDuo uncovered subclonal transcriptomic hybridization and unveiled distinct cell-states which arise in direct consequence of homotypic cell-cell fusion. CMDuo is a platform that enables mapping of cell-cell fusion events in high-throughput single cell data and enables the study of cell fusion in disease progression and therapeutic response.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785005 | PMC |
http://dx.doi.org/10.1101/2024.12.11.627873 | DOI Listing |
Genetics
September 2025
The University of Texas at Arlington, 701 South Nedderman Drive, Arlington, TX 76019, USA.
Physical interactions between cells can profoundly impact cell fate. A vital cell fate for normal development and homeostasis is programmed cell death. Cells fated to die must be efficiently cleared via phagocytosis, with defects associated with a variety of diseases.
View Article and Find Full Text PDFMol Ther Oncol
September 2025
TUM School of Medicine - Clinical Department of Internal Medicine II, TUM University Hospital, 81675 Munich, Germany.
Recent work has indicated that oncolytic virotherapy leads to immunogenic cell death (ICD) as an important mechanism of action; however, the underlying cell death pathways leading to ICD have been less explored. Our previous data demonstrated that chimeric oncolytic recombinant vesicular stomatitis virus-Newcastle disease virus (rVSV-NDV) has a strong immune-stimulating potential that seems to be mediated by immunogenic syncytial oncolysis. In this work, we aimed to investigate the role of apoptosis and necroptosis in mediating syncytial cell death.
View Article and Find Full Text PDFJ Clin Med
August 2025
Department of Morpho-Functional Sciences I, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
: The epiphyseal vascularization of long bones generates a particular flow pattern that is important for adequate angiogenesis to be achieved. Imaging reveals that vessel development in murine long bone involves the expansion and anastomotic fusion of endothelial buds. Impaired blood flow leads to defective angiogenesis and osteogenesis and downregulation of Notch signaling in endothelial cells.
View Article and Find Full Text PDFJ Med Chem
August 2025
Institute of Biomedicine of the University of Barcelona (IBUB), Universitat de Barcelona, Barcelona 08028, Spain.
Novel antiviral drugs are needed to prepare for infections from influenza A virus (IAV). Here, a series of -[(thiophen-3-yl)methyl]benzamides, which target the hemagglutinin (HA)-mediated fusion process, is reported. The most active compound, , displays a 50% effective concentration (EC) of ∼0.
View Article and Find Full Text PDFMethods Mol Biol
August 2025
Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY, USA.
The methods detailed here measure the membrane fusion activity of viral fusion proteins and are optimized for the respiratory syncytial virus (RSV). RSV utilizes a class I fusion protein (F) to facilitate fusion between a viral and cellular membrane to allow viral entry into host cells. This process is carried out with the assistance of the glycoprotein (G), which attaches to the host-cell surface, allowing F to interact with the target cell.
View Article and Find Full Text PDF